Movano Inc. — Form 10-Q Summary
Entity note: The request metadata names Corvex, Inc., but the supplied filing is for Movano Inc. (Nasdaq: MOVE). Confirm the filing is for the intended company.
Business context and reporting period
Quarterly period ended September 30, 2022; results cover the three and nine months ended that date. Movano is a development-stage healthcare technology company developing a platform and smart ring intended to provide health and wellness measurements. It had not completed product development or recorded revenue by September 30, 2022.
Financial results and liquidity
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $5.146m | $3.803m | $13.849m | $8.928m |
| General and administrative expense | $3.511m | $1.376m | $8.592m | $4.563m |
| Total operating expenses / operating loss | $8.657m | $5.179m | $22.441m | $13.491m |
| Net loss | $8.602m | $5.173m | $22.402m | $15.468m |
| Net loss per share | $0.26 | $0.16 | $0.68 | $0.74 |
| Cash used in operating activities | Not provided quarterly | $18.590m | $11.067m |
At September 30, 2022, cash and cash equivalents were $15.945m and short-term investments were $0.822m, totaling $16.767m. Current assets were $18.088m and current liabilities $4.367m. Total liabilities were $4.796m; these included lease liabilities, and the filing reports no outstanding convertible notes or warrant liabilities. Stockholders’ equity was $14.657m and accumulated deficit was $87.170m. No gross margin is meaningful because the company had no revenue.
Material changes versus the prior comparable period
- Q3 operating expenses rose 67% year over year; R&D increased 35% and G&A increased 155%. Management attributed the increases primarily to company growth, activity, and higher compensation and related costs.
- Q3 net loss increased to $8.602m from $5.173m. For the first nine months, net loss increased to $22.402m from $15.468m, while 2021 included $1.977m of net other expense, including convertible-note interest and noncash fair-value changes.
- Operating cash use increased to $18.590m from $11.067m for the nine-month period. Cash and cash equivalents declined $1.730m from year-end 2021; investment maturities provided $15.004m of investing cash, while ATM stock sales provided $1.921m of financing cash.
- Short-term investments declined from $15.921m at December 31, 2021 to $0.822m at September 30, 2022, largely reflecting maturities. Common shares outstanding increased to 33.492m from 32.772m at year-end.
Outlook, risks, contingencies, and unusual items
- Management expects significant expenses and increasing operating losses for at least the next several years as it develops products, prepares for regulatory submissions, and plans manufacturing and commercialization. The filing gives no specific revenue, launch, or earnings guidance.
- The company states that available cash and investments are insufficient to complete product development and commercialization, expects to need additional financing, and identifies substantial doubt about its ability to continue as a going concern within one year after issuance of the financial statements. Failure to obtain funding could delay, reduce, or end development or commercialization plans.
- An at-the-market program established in August 2022 permits up to $50m of stock sales. The company sold 674,191 shares for $1.9m net during Q3; approximately $48m of offering capacity remained at September 30. Further equity sales may dilute stockholders.
- Key risks include product feasibility and commercialization, reliance on third parties, competition, access to capital, intellectual property, and obtaining required FCC, FDA, and other regulatory approvals. COVID-19’s long-term business impact could not be estimated.
- Management reported disclosure controls were ineffective at September 30, 2022, citing a material weakness in financial close and reporting controls, including account reviews and certain IT general controls. Remediation efforts may not be sufficient.
- There were no material pending legal proceedings identified by management. The filing reports ordinary-course indemnification arrangements with potential future exposure that cannot be quantified. The company adopted ASC 842 lease accounting in 2022; management said adoption had no material effect on results or cash flows.
Most important facts for investors to verify
- Confirm that Movano Inc., rather than Corvex, Inc., is the intended issuer.
- Assess cash runway against operating cash burn and the company’s stated going-concern uncertainty; verify subsequent financing and ATM sales.
- Track product development, clinical or technical validation, regulatory requirements, and any commercialization milestones; the filing reports no revenue and provides no specific launch guidance.
- Monitor share issuance and potential dilution, including the ATM program, 7.385m outstanding options, and 1.938m warrants as of September 30, 2022.
- Review progress in remediating the disclosed material weakness and restoring effective disclosure controls.